Zimmer Biomet Eyes Faster Growth in 2027, Targets Earlier Robotics Launch

Zimmer Biomet (NYSE:ZBH) expects revenue growth to improve in 2027 after exceeding its own expectations in each of the first three quarters of 2026, CEO Ivan Tornos said during a Jefferies fireside chat.

Tornos pointed to a diminishing headwind in China, progress in the company’s U.S. sales force transition and new product launches as potential contributors. He also announced that Zimmer Biomet had filed a 510(k) submission with the U.S. Food and Drug Administration for its Monogram surgical robotics platform.

“Our expectations are we’re going to be launching in the year 2027,” Tornos said of Monogram, while noting that the launch depends on the FDA’s review. He said the company expects to introduce it as a surgeon-guided autonomous platform sooner than the 2028 timeframe it had previously contemplated.

Third-quarter growth and knee performance

Tornos said global hip revenue grew 7% in the third quarter, including 5.8% growth in the U.S. and 8.2% outside the country. The company’s SET businesses grew 7.1% globally, with foot and ankle growth of 18.4% and CMFT growth of 15%.

Technology revenue grew 24% for the quarter, including 34.6% in the U.S., he said. Zimmer Biomet reports technology alongside surgical and other revenue.

Knees were a weaker area. Tornos said changes to the U.S. go-to-market model affected the franchise, contributing to a 2% decline in U.S. knee revenue. He said knee revenue would have been flat globally excluding China.

Zimmer Biomet continues to estimate its weighted average market growth rate at 4.25%, Tornos said. Although the U.S. reconstructive market was slightly softer than expected in the quarter, he said indicators such as cancellation rates, waiting lists and referral cycles had not shown evidence of a structural change in market growth.

Monogram and iodine-coated implants

Tornos said the Monogram submission followed a clinical trial that reported zero safety events. He described potential advantages in efficiency, ease of use, reproducibility and accuracy, while cautioning that the company must obtain the FDA claims it is seeking. He said he would not be surprised by further exchanges with the agency during its review.

The company is also looking to expand its iodine-coated implant technology beyond Japan, where it has launched a coated hip device. Tornos said the product has contributed to hip growth and carries a 40% premium when customers move from a non-coated device to an iodine-coated one.

Zimmer Biomet is working toward European authorization and discussing opportunities in the U.S. and Canada, he said. The company also intends to extend the technology to knee and shoulder products.

2027 outlook and acquisition strategy

Tornos said China represented a 50-basis-point headwind to company growth in 2026, but he expects it to become a tailwind in 2027. He also cited a full year of Paragon 28 in organic growth, the ROSA Shoulder platform and a potential Monogram launch as factors supporting the outlook.

He cautioned that the final stage of the U.S. sales force transition remains the riskiest. Of Zimmer Biomet’s 2,540 U.S. representatives, 75% now work exclusively for the company, Tornos said. The company plans to continue the transition through 2027.

Zimmer Biomet aims to raise its weighted average market growth rate to 6% by 2030. Tornos said the company believes it can achieve about half of the required increase organically, with acquisitions providing the rest. He identified higher-growth reconstructive products, SET, neuro and ambulatory surgery center opportunities as areas of interest.

Margins and cash flow

Interim CFO Paul Stellato said revenue growth, manufacturing footprint changes and inventory simplification could support longer-term gross margin expansion. He noted that Zimmer Biomet had announced a Swiss facility shutdown and opened a Costa Rica facility earlier in the year.

Stellato also said the company’s 46.5% operating expense profile was not sustainable, and pointed to technology and a global capability center in India as potential sources of efficiency.

Tornos said Zimmer Biomet expects to generate close to $2 billion in operating cash flow and roughly $1.3 billion to $1.4 billion in free cash flow for 2026. The company plans to prioritize a stable dividend, strategic acquisitions and share repurchases, including close to $500 million in buybacks in the fourth quarter, he said.

About Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.